FY2025 EPS Estimates for Zoetis Lifted by Leerink Partnrs

Key Points

• Leerink Partners has revised its FY2025 EPS estimates for Zoetis upward to $6.37 per share, an increase from the previous estimate of $6.25.
• Zoetis reported a quarterly EPS of $1.76, exceeding analysts' expectations of $1.62, along with revenues of $2.46 billion, which surpassed projections of $2.41 billion.
• Zoetis will pay a quarterly dividend of $0.50 per share on September 3rd, reflecting an annualized yield of 1.4%.

Zoetis Inc. (NYSE:ZTS - Free Report) - Leerink Partnrs raised their FY2025 earnings estimates for shares of Zoetis in a report issued on Tuesday, August 5th. Leerink Partnrs analyst D. Clark now anticipates that the company will earn $6.37 per share for the year, up from their prior forecast of $6.25. Leerink Partnrs has a "Hold" rating on the stock. The consensus estimate for Zoetis' current full-year earnings is $6.07 per share.

Several other equities analysts have also recently weighed in on ZTS. UBS Group decreased their target price on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Stifel Nicolaus cut shares of Zoetis from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Leerink Partners cut shares of Zoetis from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Finally, Piper Sandler lifted their price objective on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Monday, May 12th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, Zoetis currently has a consensus rating of "Moderate Buy" and an average target price of $204.63.

Zoetis Stock Down 0.6%

Shares of Zoetis stock traded down $0.90 during trading hours on Friday, reaching $147.34. 2,062,093 shares of the company's stock were exchanged, compared to its average volume of 3,804,772. The company has a 50 day moving average of $156.71 and a two-hundred day moving average of $159.76. Zoetis has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The stock has a market cap of $65.30 billion, a P/E ratio of 25.36, a P/E/G ratio of 2.41 and a beta of 0.88.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same period last year, the company posted $1.56 EPS. The business's quarterly revenue was up 4.2% on a year-over-year basis.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis's payout ratio is presently 34.42%.

Insider Activity

In other news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the sale, the executive vice president owned 15,129 shares of the company's stock, valued at approximately $2,571,930. The trade was a 4.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.18% of the company's stock.

Institutional Investors Weigh In On Zoetis

Institutional investors have recently modified their holdings of the business. Nova Wealth Management Inc. bought a new stake in shares of Zoetis in the first quarter valued at about $25,000. 1248 Management LLC acquired a new position in Zoetis in the first quarter valued at about $27,000. Saudi Central Bank acquired a new position in Zoetis in the first quarter valued at about $29,000. Navigoe LLC acquired a new position in Zoetis in the fourth quarter valued at about $30,000. Finally, Cornerstone Planning Group LLC raised its stake in Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after purchasing an additional 88 shares in the last quarter. Institutional investors own 92.80% of the company's stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.